161 related articles for article (PubMed ID: 34394228)
1. Improved antimalarial activity of caprol-based nanostructured lipid carriers encapsulating artemether-lumefantrine for oral administration.
Akpa PA; Ugwuoke JA; Attama AA; Ugwu CN; Ezeibe EN; Momoh MA; Echezona AC; Kenechukwu FC
Afr Health Sci; 2020 Dec; 20(4):1679-1697. PubMed ID: 34394228
[TBL] [Abstract][Full Text] [Related]
2. Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance.
Nnamani PO; Ugwu AA; Ibezim EC; Kenechukwu FC; Akpa PA; Ogbonna JN; Obitte NC; Odo AN; Windbergs M; Lehr CM; Attama AA
Int J Nanomedicine; 2016; 11():6365-6378. PubMed ID: 27932882
[TBL] [Abstract][Full Text] [Related]
3. Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity.
Parashar D; Aditya NP; Murthy RS
Drug Deliv; 2016; 23(1):123-9. PubMed ID: 24786480
[TBL] [Abstract][Full Text] [Related]
4. Artemether-lumefantrine nanostructured lipid carriers for oral malaria therapy: Enhanced efficacy at reduced dose and dosing frequency.
Prabhu P; Suryavanshi S; Pathak S; Sharma S; Patravale V
Int J Pharm; 2016 Sep; 511(1):473-487. PubMed ID: 27421912
[TBL] [Abstract][Full Text] [Related]
5. Nanostructured lipid carriers of artemether-lumefantrine combination for intravenous therapy of cerebral malaria.
Prabhu P; Suryavanshi S; Pathak S; Patra A; Sharma S; Patravale V
Int J Pharm; 2016 Nov; 513(1-2):504-517. PubMed ID: 27596113
[TBL] [Abstract][Full Text] [Related]
6. In vivo Antiplasmodial Activity of Curcumin-Loaded Nanostructured Lipid Carriers.
Rashidzadeh H; Salimi M; Sadighian S; Rostamizadeh K; Ramazani A
Curr Drug Deliv; 2019; 16(10):923-930. PubMed ID: 31663477
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antimalarial activity by a novel artemether-lumefantrine lipid emulsion for parenteral administration.
Ma Y; Lu T; Zhao W; Wang Y; Chen T; Mei Q; Chen T
Antimicrob Agents Chemother; 2014 Oct; 58(10):5658-65. PubMed ID: 24982079
[TBL] [Abstract][Full Text] [Related]
8. Ameliorating the in vivo antimalarial efficacy of artemether using nanostructured lipid carriers.
Vanka R; Kuppusamy G; Praveen Kumar S; Baruah UK; Karri VVSR; Pandey V; Babu PP
J Microencapsul; 2018 Mar; 35(2):121-136. PubMed ID: 29448884
[TBL] [Abstract][Full Text] [Related]
9. Formulation design, in vitro characterizations and anti-malarial investigations of artemether and lumefantrine-entrapped solid lipid microparticles.
Agbo C; Umeyor C; Kenechukwu F; Ogbonna J; Chime S; Lovelyn C; Agubata O; Ofokansi K; Attama A
Drug Dev Ind Pharm; 2016 Oct; 42(10):1708-21. PubMed ID: 27095388
[TBL] [Abstract][Full Text] [Related]
10. Optimization and evaluation of lipid emulsions for intravenous co-delivery of artemether and lumefantrine in severe malaria treatment.
Yang Y; Gao H; Zhou S; Kuang X; Wang Z; Liu H; Sun J
Drug Deliv Transl Res; 2018 Oct; 8(5):1171-1179. PubMed ID: 29748832
[TBL] [Abstract][Full Text] [Related]
11. Novel transdermal bioadhesive surfactant-based system for release and solubility improvement of antimalarial drugs artemether-lumefantrine.
Volpe-Zanutto F; Fonseca-Santos B; McKenna PE; Paredes AJ; Dávila JL; McCrudden MTC; Tangerina MMP; Ceccheto Figueiredo M; Vilegas W; Brisibe A; Akira D'Ávila M; Donnelly RF; Chorilli M; Foglio MA
Biomed Mater; 2021 Oct; 16(6):. PubMed ID: 34544052
[TBL] [Abstract][Full Text] [Related]
12. Vitamin C-rich juice co-administration with artemether-lumefantrine ameliorates oxido-inflammatory responses in Plasmodium berghei-infected mice.
Ajayi AM; Adebanjo IM; Ademowo OG
Parasitol Res; 2023 Aug; 122(8):1841-1850. PubMed ID: 37256314
[TBL] [Abstract][Full Text] [Related]
13. Parasite impairment by targeting Plasmodium-infected RBCs using glyceryl-dilaurate nanostructured lipid carriers.
Jain SA; Basu H; Prabhu PS; Soni U; Joshi MD; Mathur D; Patravale VB; Pathak S; Sharma S
Biomaterials; 2014 Aug; 35(24):6636-45. PubMed ID: 24818881
[TBL] [Abstract][Full Text] [Related]
14. Nanoliposomes Embedded Nanocochleates for Codelivery of Artemether and Lumefantrine: An
Mathure D; Sonawane P; Ranpise H; Awasthi R
Assay Drug Dev Technol; 2024; 22(2):63-72. PubMed ID: 38193797
[No Abstract] [Full Text] [Related]
15. Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.
Hamaluba M; van der Pluijm RW; Weya J; Njuguna P; Ngama M; Kalume P; Mwambingu G; Ngetsa C; Wambua J; Boga M; Mturi N; Lal AA; Khuroo A; Taylor WRJ; Gonçalves S; Miotto O; Dhorda M; Mutinda B; Mukaka M; Waithira N; Hoglund RM; Imwong M; Tarning J; Day NPJ; White NJ; Bejon P; Dondorp AM
Lancet Infect Dis; 2021 Oct; 21(10):1395-1406. PubMed ID: 34111412
[TBL] [Abstract][Full Text] [Related]
16. Developmental stages influence in vivo antimalarial activity of aerial part extracts of Schkuhria pinnata.
Nuwagira C; Peter EL; Ajayi CO; Adriko J; Kagoro GR; Olet EA; Ogwang PE; Tolo CU
J Ethnopharmacol; 2021 Oct; 279():114341. PubMed ID: 34144195
[TBL] [Abstract][Full Text] [Related]
17. In vivo efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology.
du Plessis LH; Govender K; Denti P; Wiesner L
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):68-77. PubMed ID: 26478276
[TBL] [Abstract][Full Text] [Related]
18. Artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers.
Koko VS; Warsame M; Vonhm B; Jeuronlon MK; Menard D; Ma L; Taweh F; Tehmeh L; Nyansaiye P; Pratt OJ; Parwon S; Kamara P; Asinya M; Kollie A; Ringwald P
Malar J; 2022 Apr; 21(1):134. PubMed ID: 35477399
[TBL] [Abstract][Full Text] [Related]
19. Development of artemether-loaded nanostructured lipid carrier (NLC) formulation for topical application.
Nnamani PO; Hansen S; Windbergs M; Lehr CM
Int J Pharm; 2014 Dec; 477(1-2):208-17. PubMed ID: 25290810
[TBL] [Abstract][Full Text] [Related]
20. Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation.
Khan S; Baboota S; Ali J; Narang RS; Narang JK
Drug Dev Ind Pharm; 2016; 42(2):209-20. PubMed ID: 26016780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
